2-溴-N,2-二甲基-丙酰胺 | 69959-88-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-溴-N,2-二甲基-丙酰胺
• 英文名称: 2-bromo-N,2-dimethylpropanamide
• CAS: 69959-88-2
• 化学式: C₅H₁₀BrNO
• mdl: MFCD03413096
• 分子量: 180.044
• InChiKey: JJDUHFSDEPSCOX-UHFFFAOYSA-N

物化性质

• 熔点：
  38-39°C

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2924199090
• 储存条件：
  存储条件：2-8°C，密封保存，并置于干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Methyl 2-bromoisobutyramide
Synonyms: N,2-Dimethyl 2-bromopropanamide; 2-Bromo-N,2-dimethylpropanamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Methyl 2-bromoisobutyramide
CAS number: 69959-88-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H10BrNO
Molecular weight: 180.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-N,2-二甲基-丙酰胺 在 水 、 silver(l) oxide 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以75%的产率得到α-hydroxy isobutyric acid N-methyl amide
  参考文献：
  名称：

  溴酰胺作为合成α-羟基和α-烷氧基衍生物的原料

  摘要：

  摘要 氧化银促进 α - 溴甲酰胺的 2 位溴被羟基或烷氧基取代。

  DOI：

  10.1080/00397919408019046
• 作为产物：
  描述：

  2-溴-2-甲基丙酰溴 、 甲胺 以 四氢呋喃 为溶剂， 反应 0.5h， 以82.4%的产率得到2-溴-N,2-二甲基-丙酰胺
  参考文献：
  名称：

  NAPHTHYRIDINES AS INHIBITORS OF HPK1

  摘要：

  萘啶化合物及其作为HPK1抑制剂的用途被描述。这些化合物在治疗HPK1依赖性疾病和增强免疫反应方面很有用。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备萘啶化合物的方法。

  公开号：

  US20180282328A1

文献信息

• [EN] FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES<br/>[FR] PYRROLE CARBOXAMIDES SUBSTITUÉS PAR UN FLUOROMÉTHYLE
  申请人：GRUENENTHAL GMBH

  公开号：WO2014032801A1

  公开（公告）日：2014-03-06

  The invention relates to pyrrole carboxamides bearing a fluoromethyl- moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  这项发明涉及带有氟甲基基团的吡咯羧酰胺作为电压门控钙通道阻滞剂，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
• FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES
  申请人：GRUNENTHAL GMBH

  公开号：US20140066426A1

  公开（公告）日：2014-03-06

  The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  这项发明涉及带有氟甲基基团的吡咯酮羧酰胺作为电压门控钙通道阻滞剂，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
• Formation of quaternary carbons through cobalt-catalyzed C(sp³)–C(sp³) Negishi cross-coupling
  作者：Eduardo Palao、Enol López、Iván Torres-Moya、Antonio de la Hoz、Ángel Díaz-Ortiz、Jesús Alcázar

  DOI：10.1039/d0cc02734k

  日期：——

  quaternary carbons is a key challenge in organic and medicinal chemistry. We report a cobalt-catalyzed C(sp3)–C(sp3) cross-coupling that allows for the introduction of benzyl, heteroarylmethylzinc and allyl groups to halo-carbonyl substrates. The cross-coupling reaction is selective for C(sp3)-over C(sp2)-halides, in contrast to most used catalytic metals, and allows access to novel scaffolds of pharmaceutical

  全碳取代的季碳的形成是有机和药物化学中的关键挑战。我们报告了钴催化的C（sp 3）–C（sp 3）交叉偶联，可将苄基，杂芳基甲基锌和烯丙基引入卤代羰基底物。与大多数使用的催化金属相反，交叉偶联反应对C（sp 3）-比C（sp 2）-卤化物具有选择性，并允许使用新的药物感兴趣的支架。NMR机理研究表明Co（0）配合物作为催化物质的存在。
• Copper-Catalyzed Ring-Opening Defluorinative Alkylation of Siloxydifluorocyclopropanes: Synthesis of γ-Fluoro-δ-Ketoesters and γ,δ-Diketonitriles
  作者：Shifang Wang、Xiaowei Liu、Dongsheng Zhu、Mang Wang

  DOI：10.1021/acs.joc.0c01643

  日期：2020.10.2

  fluorinated synthons and homoenolate equivalents, synthetic application of difluorocyclopropanols is desired but remains challenging due to their thermodynamic instability. Herein, we use siloxydifluorocyclopropanes as difluorocyclopropanol precursors to carry out new Cu-catalyzed ring-opening defluorinative alkylation. With α-bromo carboxylic esters as coupling partners, the reaction affords γ-fluoro-δ-ketoesters

  考虑到氟化合成子和均烯酸酯等同物的重要性，期望合成应用二氟环丙醇，但是由于它们的热力学不稳定性而仍然具有挑战性。本文中，我们使用甲硅烷氧基二氟环丙烷作为二氟环丙醇的前体，以进行新的Cu催化的开环脱氟烷基化反应。以α-溴代羧酸酯为偶联伙伴，该反应通过Cu I / Cu II催化循环提供了γ-氟代-δ-酮酸酯。有趣的是，通过使用α-溴酰胺，在开环脱氟烷基化之后，进行了额外的分子内C–N氧化偶联，以提供内酰胺中间体，该内酰胺中间体进一步经历了脱氟，水解，开环和脱水级联反应通过Cu I / Cu II / Cu III催化途径，导致最终产物γ，δ-二酮腈。
• BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076292A1

  公开（公告）日：2011-03-31

  Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  方程式I中的苯并噁唑啉化合物，包括立体异构体、几何异构体、互变异构体、溶剂合物、代谢物及其药用可接受盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；B为与苯并噁唑啉环融合的吡唑基、咪唑基或三唑基环，用于抑制脂质激酶包括p110 alpha和PI3K的其他同系物，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用方程式I中的化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理条件的方法。